RESUMO
Introduction: Subthalamic nucleus (STN) deep brain stimulation (DBS) is an important option in the treatment of motor symptoms and fluctuations in patients with advanced Parkinson's disease (PD). In addition to the improvement in motor symptoms, many studies have reported changes in some non-motor symptoms (NMS) after STN DBS.Method: 61 patients (42 males) who underwent STN DBS with advanced PD and 24 healthy controls (15 males) were included in the study. Autonomic symptoms (orthostatic hypotension, sweating, salivation) were assessed with a semi-structured questionnaire. Sympathetic skin responses (SSR) were studied by electrophysiological examination within 3-6 months after STN DBS.Results: SSR latency and amplitude were found between the control group and preoperative patients (P ≤ 0.01; p = 0.01, respectively), and between preoperative and postoperative patients (P ≤ 0.01; P ≤ 0.01, respectively). There was a statistically significant difference between the control group and postoperative patients (p = 0.005; p = 0.029, respectively). Orthostatic hypotension (29%) and sweating (48%) improved, but there was no change in the salivation.Discussion: We think that STN DBS applied in PD has not only motor symptoms and fluctuations, but also corrects autonomic dysfunctions such as sweating disorders and orthostatic hypotension; SSR is more sensitive and reliable in detecting autonomic dysfunction, independent of motor symptoms and fluctuations.
Assuntos
Estimulação Encefálica Profunda/métodos , Hipotensão Ortostática/fisiopatologia , Doença de Parkinson/terapia , Sialorreia/fisiopatologia , Sudorese/fisiologia , Idoso , Eletrofisiologia , Feminino , Humanos , Hipotensão Ortostática/etiologia , Masculino , Pessoa de Meia-Idade , Doença de Parkinson/complicações , Doença de Parkinson/fisiopatologia , Sialorreia/etiologia , Núcleo Subtalâmico/fisiologiaRESUMO
Sialorrhea, or excessive saliva beyond the margin of the lip, is a common problem in many neurological diseases. Previously, sialorrhea has been underrecognized in Parkinson's disease (PD) patients. Despite this, many patients rank sialorrhea as one of the most debilitating complaints of Parkinson's disease. Previous treatment for sialorrhea has been suboptimal and has been plagued by significant side effects that are bothersome and can be dangerous in patients with a concurrent neurodegenerative disease. This review sought to review the anatomy, function, and etiology of sialorrhea in PD. It then sought to examine the evidence for the different treatments of sialorrhea in PD, and further examined newer evidence for safety and efficacy in minimally invasive treatment such as botulinum toxin.
Assuntos
Doença de Parkinson/complicações , Glândulas Salivares/fisiopatologia , Salivação , Sialorreia/etiologia , Inibidores da Liberação da Acetilcolina/uso terapêutico , Animais , Toxinas Botulínicas Tipo A/uso terapêutico , Humanos , Doença de Parkinson/diagnóstico , Doença de Parkinson/fisiopatologia , Glândulas Salivares/efeitos dos fármacos , Salivação/efeitos dos fármacos , Sialorreia/diagnóstico , Sialorreia/tratamento farmacológico , Sialorreia/fisiopatologia , Resultado do TratamentoRESUMO
BACKGROUND: Drooling is dependent on various clinical variables. However, while drooling proves refractory to two-duct ligation in 40% of patients, predictors for treatment success are sparse and to date there is little evidence why some respond well while others are non-responders. We aim to find predictors for treatment success and study the effectiveness of two-duct ligation for drooling in neurodisabilities. METHODS: Fifty-four patients with moderate to severe drooling who had undergone two-duct ligation were screened for inclusion. Four patients were excluded due to missing or unreliable primary outcomes. The average age at the time of surgery was 12 years. Predictors were evaluated for treatment success which was defined as ≥ 50% visual analog scale for severity of drooling and/or drooling quotient reduction from baseline. Treatment effect was measured after 8 and 32 weeks compared to baseline. RESULTS: Age (more mature), adequate posture (no anteflexion), and normal speech are predictors for treatment success. Compared to baseline, drooling quotient was significantly lower at 8 (difference 18.6%, 95% confidence interval 12.3-24.9%) and 32 weeks (difference 10.1%, 95% confidence interval 3.9-16.4%). Compared to baseline, visual analog scale was significantly lower at 8 (difference 45.0, 95% confidence interval 37.0-52.9) and 32 weeks (difference 32.9, 95% confidence interval 25.0-40.7). CONCLUSIONS: Age, adequate posture, and a normal speech are predictors for treatment success, are easily determined pre-operatively, and help the clinician providing patient-specific probability of treatment success. There is a significant subjective and objective decrease of drooling after two-duct ligation.
Assuntos
Paralisia Cerebral/complicações , Transtornos do Neurodesenvolvimento/complicações , Procedimentos Cirúrgicos Bucais , Avaliação de Resultados em Cuidados de Saúde , Sialorreia/etiologia , Sialorreia/cirurgia , Glândula Submandibular/cirurgia , Adolescente , Criança , Tomada de Decisão Clínica , Feminino , Seguimentos , Humanos , Ligadura , Masculino , Procedimentos Cirúrgicos Bucais/efeitos adversos , Procedimentos Cirúrgicos Bucais/métodos , Prognóstico , Estudos Retrospectivos , Índice de Gravidade de Doença , Sialorreia/fisiopatologiaRESUMO
INTRODUCTION: Angiotensin converting enzyme inhibitor (ACEi) associated angioedema is frequently encountered in the emergency department. Airway management is the primary treatment, but published evidence supporting the decision to intubate patients with this condition is extremely limited. METHOD: We performed a retrospective study of all cases of ACEi associated angioedema encountered in a large, urban, tertiary referral emergency department. We classified demographics, duration of symptoms before presentation, physical exam findings and nasopharyngoscopy findings in patients that did and did not require intubation. RESULTS: We identified a total of 190 separate encounters from 183 unique patients who presented during the 3-year period of the study. Eighteen (9.5%) of these patients required intubation. Patients requiring intubation were more likely to present within 6 h of the onset of angioedema symptoms. Anterior tongue swelling, vocal changes, drooling, and dyspnea were significantly more common in patients requiring intubation. Isolated lip swelling was present in 54% of all patients and was the only finding significantly more common in the group that did not require intubation. CONCLUSIONS: Rapid progression of symptoms within the first 6 h of angioedema onset, anterior tongue swelling, vocal changes, drooling and dyspnea are associated with intubation for ACEi associated angioedema. Isolated lip swelling is significantly more common in patients that do not require intubation. Our data provide risk stratification guidance for providers treating patients with suspected ACEi associated angioedema in the emergency department.
Assuntos
Manuseio das Vias Aéreas , Angioedema/terapia , Inibidores da Enzima Conversora de Angiotensina/efeitos adversos , Intubação Intratraqueal/estatística & dados numéricos , Lábio , Língua , Idoso , Angioedema/induzido quimicamente , Angioedema/fisiopatologia , Estudos de Casos e Controles , Dispneia/fisiopatologia , Serviço Hospitalar de Emergência , Feminino , Humanos , Laringoscopia , Masculino , Pessoa de Meia-Idade , Medição de Risco , Sialorreia/fisiopatologia , Fatores de Tempo , Distúrbios da Voz/fisiopatologiaRESUMO
BACKGROUND: Botulinum neurotoxin (BoNT) is an effective treatment for chronic sialorrhea; however, reliable and robust evidence supporting long-term efficacy and safety is lacking. This study investigated the efficacy and safety of repeated incobotulinumtoxinA injections for chronic sialorrhea over 64 weeks. METHODS: Adults with sialorrhea were randomized (2:2:1) to incobotulinumtoxinA 75 U, incobotulinumtoxinA 100 U (n = 74 each), or placebo (n = 36) in the double-blind, placebo-controlled main period (NCT02091739). Eligible subjects entered the extension period and received dose-blinded incobotulinumtoxinA 75 or 100 U in three further 16±2-week injection cycles. Efficacy and safety assessments in subjects who received incobotulinumtoxinA throughout the study included unstimulated salivary flow rate (uSFR), subjects' Global Impression of Change Scale (GICS), Drooling Severity and Frequency Scale (DSFS), modified Radboud Oral Motor Inventory for Parkinson's Disease (mROMP) drooling, speech, and swallowing symptom scores, and incidence of adverse events (AEs). RESULTS: In total, 173/184 subjects (94%) completed the main period and entered the extension period; 141 subjects received incobotulinumtoxinA 75 U (n = 69) or 100 U (n = 72) in both periods. Mean uSFR decreased consistently with repeated incobotulinumtoxinA 75 and 100 U treatment and by -0.16 and -0.17, respectively, at the end-of-study visit. Subjects' GICS, DSFS, and mROMP drooling scores also improved at all assessments. mROMP speech and swallowing scores remained stable. The most common treatment-related AEs during the extension period were dry mouth (4.4% and 11.1%) and dysphagia (1.5% and 4.2%). CONCLUSIONS: Data support long-term efficacy and safety of repeated incobotulinumtoxinA treatment for sialorrhea, with no additional safety concerns reported over 64 weeks.
Assuntos
Toxinas Botulínicas Tipo A/farmacologia , Encefalopatias/complicações , Fármacos Neuromusculares/farmacologia , Avaliação de Resultados em Cuidados de Saúde , Sialorreia/tratamento farmacológico , Sialorreia/fisiopatologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Toxinas Botulínicas Tipo A/administração & dosagem , Toxinas Botulínicas Tipo A/efeitos adversos , Doença Crônica , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fármacos Neuromusculares/administração & dosagem , Fármacos Neuromusculares/efeitos adversos , Doença de Parkinson/complicações , Estudos Prospectivos , Sialorreia/etiologia , Fatores de Tempo , Adulto JovemRESUMO
Background: Drooling is an involuntary loss of saliva from the mouth, and it is a common problem for children with cerebral palsy (CP). The treatment may be pharmacological, surgical, or speech-related. Repeated Muscle Vibration (rMV) is a proprioceptive impulse that activates fibers Ia reaching the somatosensory and motor cortex. Aim: The aim of the study is to evaluate the effectiveness of rMV in the treatment of drooling in CP. Design, setting and population: This was a rater blinded prospective feasibility study, performed at the "Gli Angeli di Padre Pio" Foundation, Rehabilitation Centers (Foggia, Italy), involving twenty-two CP patients affected by drooling (aged 5-15, mean 9,28 ± 3,62). Children were evaluated at baseline (T0), 10 days (T1), 1 month (T2) and 3 months (T3) after the treatment. Methods: The degree and impact of drooling was assessed by using the Drooling Impact Scale (DIS), the Drooling Frequency and Severity Scale (DFSS), Visual Analogue Scale (VAS) and Drooling Quotient (DQ). An rMV stimulus under the chin symphysis was applied with a 30 min protocol for 3 consecutive days. Results: The statistical analysis shows that DIS, DFSS, VAS, DQ improved with significant differences in the multiple comparisons between T1 vs T2, T1 vs T3 and T1 vs T4 (p≤0.001). Conclusion This study demonstrates that rMV might be a safe and effective tool in reducing drooling in patients with CP. The vibrations can improve the swallowing mechanisms and favor the acquisition of the maturity of the oral motor control in children with CP.
Assuntos
Paralisia Cerebral/terapia , Músculos/fisiopatologia , Sialorreia/terapia , Vibração/uso terapêutico , Adolescente , Paralisia Cerebral/fisiopatologia , Criança , Pré-Escolar , Estudos de Viabilidade , Feminino , Humanos , Masculino , Modalidades de Fisioterapia , Estudos Prospectivos , Sialorreia/fisiopatologia , Sialorreia/prevenção & controleRESUMO
Sialorrhea is often treated with anticholinergic agents, but they can have undesirable side effects such as drowsiness, sedation, and constipation. Effective medication that acts selectively on the salivary glands is needed. We report the case of a patient with sialorrhea who was successfully treated by the combined use of pirenzepine and solifenacin (M1 and M3 muscarinic receptor antagonists, respectively). The patient was a 51-year-old man with mean unstimulated and stimulated salivary flow rates per 10 min of 6.1 mL and 41.7 mL, respectively (both were measured three times). 99mTcO4- salivary gland scintigraphy revealed characteristic spontaneous saliva secretion without stimulation. He was treated with Scopolia extract, escitalopram, solifenacin succinate, and the combined administration of solifenacin succinate and pirenzepine. A statistically significant decrease was observed from the pre-medication unstimulated and stimulated salivary flow rates only following the combined administration of solifenacin and pirenzepine. The major muscarinic receptor subtype expressed in the salivary glands is M3; however, M1 is also present. A study using knockout mice demonstrated that the presence of either M1 or M3 receptors was sufficient for salivation. Thus, the combined use of selective M1 and M3 antagonists could provide a good treatment option for sialorrhea.
Assuntos
Antagonistas Muscarínicos/administração & dosagem , Pirenzepina/administração & dosagem , Receptor Muscarínico M1/antagonistas & inibidores , Receptor Muscarínico M3/antagonistas & inibidores , Sialorreia/tratamento farmacológico , Succinato de Solifenacina/administração & dosagem , Animais , Quimioterapia Combinada , Humanos , Masculino , Camundongos Knockout , Pessoa de Meia-Idade , Cintilografia , Receptor Muscarínico M1/fisiologia , Receptor Muscarínico M3/fisiologia , Glândulas Salivares/diagnóstico por imagem , Glândulas Salivares/fisiopatologia , Salivação , Sialorreia/diagnóstico por imagem , Sialorreia/fisiopatologia , Resultado do TratamentoRESUMO
BACKGROUND: Ptyalism gravidarum (PG) is a condition of hypersalivation that affects pregnant women early in gestation. Symptoms include massive saliva volumes (up to 2 liters per day), swollen salivary glands, sleep deprivation, significant emotional distress, and social difficulties. OBJECTIVES: To examine maternal and fetal characteristics and pregnancy outcomes of patients with PG. METHODS: Patients diagnosed with PG in our clinic during the years 2001-2016 were identified and contacted. Demographic data were extracted from patient charts and clinical and outcome data was collected via telephone interviews. RESULTS: The incidence of PG was 1/963 (0.09%) in our sample. Eleven out of 22 women (40%) with PG were also diagnosed with hyperemesis gravidarum. Fetal gender did not increase the risk. Of the mothers presenting with PG, 37% had a positive family history for this condition. There was no associated increase in the rate of fetal or maternal complications. Two women reported a resolution of the symptoms immediately following hypnosis with acupuncture treatment. CONCLUSIONS: Although PG represents an unpleasant mental and physical condition, it does not pose any specific risk to the health of the mother or increase adverse perinatal outcomes for the fetus. Alternative medicine could play a role in the treatment of PG.
Assuntos
Complicações na Gravidez/diagnóstico , Complicações na Gravidez/fisiopatologia , Sialorreia/diagnóstico , Sialorreia/fisiopatologia , Adulto , Feminino , Humanos , Hiperêmese Gravídica/complicações , Hiperêmese Gravídica/diagnóstico , Hiperêmese Gravídica/fisiopatologia , Entrevistas como Assunto , Gravidez , Complicações na Gravidez/terapia , Estudos Retrospectivos , Sialorreia/complicaçõesRESUMO
BACKGROUND: Drooling of saliva is a common problem in children with cerebral palsy. In addition to causing impairment in articulation, drooling also affects socialization, interpersonal relationships and integration into society for these children. There are various methods to assess drooling which measure directly the amount of saliva drooled. However the most convenient and popular method is the use of questionnaires which are mostly western based and need slight modification for the Indian scenario Aim-Validation of a modified questionnaire for the assessment of drooling in children with cerebral palsy. METHOD: The modified questionnaire was administered to parents of children with cerebral palsy willing to participate in the study. The drooling score was compared with objective tests, namely cotton pad test and drooling quotient. Internal consistency was assessed using the Cronbach's alpha, test retest reliability by Intraclass Correlation and sensitivity analysis by the Receiver operating characteristic curve. RESULTS: The modified questionnaire was found to be easy to administer. The Cronbach's alpha coefficient was between 0.867 and 0.879 which implies a high degree on internal consistency. The intraclass correlation and the test retest reliability was found to be statistically significant with a p valueâ¯<â¯0.001 which show that the questionnaire was highly reliable for repeat administration as well as administration by different investigators. The ROC Area was found to be 0.94 with a standard error of 0.02 with a 95% confidence interval of 0.88-0.99, which suggests that the score has great specificity, closer agreement between specificity and sensitivity and excellent precision. CONCLUSION: Our modified questionnaire was easy to administer, highly reliable and valid with high internal consistency. A score of 24 on the questionnaire was found to be the most sensitive and specific point to discriminate between the mild and severe droolers in children with cerebral palsy.
Assuntos
Paralisia Cerebral/fisiopatologia , Pais , Sialorreia/fisiopatologia , Adolescente , Paralisia Cerebral/complicações , Criança , Pré-Escolar , Estudos Transversais , Feminino , Humanos , Índia , Relações Interpessoais , Masculino , Estudos Prospectivos , Curva ROC , Reprodutibilidade dos Testes , Saliva , Sensibilidade e Especificidade , Índice de Gravidade de Doença , Sialorreia/diagnóstico , Sialorreia/etiologia , Participação Social , Fala , Inquéritos e QuestionáriosRESUMO
Drooling is a frequently reported symptom in Parkinson's Disease (PD) with significant psychosocial impact and negative health consequences including silent aspiration of saliva with the associated risk of respiratory infections. It is suggested that in PD drooling is associated with inefficient oropharyngeal swallowing which reduces the effective clearance of saliva rather than hyper-salivation. This is compounded by unintended mouth opening and flexed posture increasing anterior loss of saliva. It is reported to occur most frequently during cognitively distracting concurrent tasks suggesting an impact from divided attention in a dual-task situation. However, this supposition has not been systematically examined. This study assessed whether frequency of saliva swallows reduced, and drooling severity and frequency increased, when people with PD engaged in a cognitively distracting task. 18 patients with idiopathic PD reporting daytime drooling on the Unified Parkinson's Disease Rating Scale (UPDRS) were recruited. They completed the Radboud Oral Motor Inventory for PD saliva questionnaire and the Montreal Cognitive Assessment. UPDRS drooling score, disease stage, duration, gender, and age were recorded. Swallow frequency and drooling severity and frequency were measured at rest and during a distracting computer-based language task. There was no significant difference between drooling severity at rest and during distraction (Wilcoxon signed rank test z = - 1.724, p = 0.085). There was a significant difference between at rest and distraction conditions for both drooling frequency (Wilcoxon signed rank test z = - 2.041, p = 0.041) and swallow frequency (Wilcoxon signed rank test z = - 3.054, p = 0.002). Participants swallowed less frequently and drooled more often during the distraction task. The frequency of saliva swallows and drooling are affected by divided attention in a dual-task paradigm. Further studies are needed to explore the exact role of attention in saliva management and the clinical applications in assessment and treatment.
Assuntos
Atenção/fisiologia , Deglutição/fisiologia , Doença de Parkinson/fisiopatologia , Doença de Parkinson/psicologia , Sialorreia/etiologia , Idoso , Idoso de 80 Anos ou mais , Estudos Transversais , Feminino , Humanos , Masculino , Doença de Parkinson/complicações , Saliva , Índice de Gravidade de Doença , Sialorreia/fisiopatologia , Sialorreia/psicologia , Estatísticas não Paramétricas , Inquéritos e Questionários , Análise e Desempenho de TarefasRESUMO
Saliva exerts multiple functions in relation to the initial digestive processes taking place in the upper parts of the gastrointestinal tract. Ingestion of food and beverages, in turn, is a strong stimulus for secretion of saliva with a differential composition depending on the neuronal stimulation pattern. This review paper provides insight into the mechanisms by which saliva acts in relation to taste, mastication, bolus formation, enzymatic digestion and swallowing. Also, the protective functions of saliva including maintenance of dental and mucosal integrity will be discussed as they indirectly influence the digestive process. The final part of this study focuses on the implications of xerostomia and salivary gland dysfunction on gastrointestinal functions.
Assuntos
Saliva/fisiologia , Glândulas Salivares/fisiologia , Salivação , Sistema Nervoso Autônomo/fisiologia , Deglutição , Digestão , Mucosa Esofágica/fisiologia , Humanos , Mastigação , Mucosa Bucal/fisiologia , Saúde Bucal , Sialorreia/complicações , Sialorreia/fisiopatologia , Paladar , Xerostomia/complicações , Xerostomia/fisiopatologiaRESUMO
BACKGROUND AND OBJECTIVE: Goldenhar syndrome (ocular-auricular-vertebral syndrome), a rare congenital condition arising from defects in the first and second brachial arches, consists in clinical variety of features ranging from facial abnormalities, ear-eye abnormalities, vertebral defects and congenital heart problems and severe obstructive sleep apnea. Due to craniofacial abnormalities, patients presents mechanical obstructive phenomena and sialorrhea that cause prone position, language's fastening, use of nasopharyngeal cannulas and tracheal intubation. METHODS: In this article, we report a case of a 16 years old child affected by Goldenhar syndrome and sialorrhea to demonstrate improvement of the daily patient management, through inoculations of botulinum toxin type A. Due to severe sialorrhea which caused tracheobronchial daily aspirations, the caregivers used an external aspirators. RESULTS: In the first infiltration (August 2016) the parotid and submandibular glands bilaterally were inoculated with incobotulinum toxin type A (Xeomin®, Merz Pharma) with dosages of 5 UI for each of them, for a total of 20 UI without clinical efficacy (no quantitative and qualitative saliva reducing during 3 months). In the second (November 2016) and third (February 2017) infiltrations each parotid and each submandibular glands were injected with a (dosage of 7 UI and 5 UI respectively (total of 24 UI of incobotulinumtoxin A) with important clinical results (saliva production and tracheo-bronchial aspirations reduced). CONCLUSION: Therefore, botulinum toxin type A could be a good and non invasive treatment of sialorrhea in Goldenhar syndrome to improve oral hygiene and daily patient management.
Assuntos
Toxinas Botulínicas Tipo A/administração & dosagem , Síndrome de Goldenhar/complicações , Fármacos Neuromusculares/administração & dosagem , Glândula Parótida/efeitos dos fármacos , Salivação/efeitos dos fármacos , Sialorreia/terapia , Glândula Submandibular/efeitos dos fármacos , Adolescente , Síndrome de Goldenhar/diagnóstico , Humanos , Injeções , Masculino , Glândula Parótida/fisiopatologia , Qualidade de Vida , Recuperação de Função Fisiológica , Índice de Gravidade de Doença , Sialorreia/diagnóstico , Sialorreia/etiologia , Sialorreia/fisiopatologia , Glândula Submandibular/fisiopatologia , Sucção , Resultado do TratamentoRESUMO
Patients with Parkinson's disease (PD) are compromised by poor oral condition due to oropharyngeal bradykinesia, dysphagia, and the side effects of treatment. Intrasalivary gland injections of Botulinum neurotoxin type A (BNT-A) have been known to treat sialorrhea effectively in these patients. However, the decreased amount of saliva reduces self-cleaning ability that deteriorates oral hygiene and increases dental caries. The aim of this study was to determine the changes in the oral microflora and saliva in patients with PD treated for sialorrhea by means of sonography-controlled BNT-A injections into the bilateral parotid and submandibular glands. Altogether, 38 persons participated in the study: 12 PD patients who were injected with BNT-A for treatment of sialorrhea and passed salivary tests before and 1 month after the injections; and 13 PD patients and 13 healthy subjects who were not injected with BNT-A and passed salivary tests once. The condition of oral health was measured by the amount of saliva, salivary flow rate, and salivary composition. A good outcome with a significant decrease in salivary flow rate occurred at 1-month follow-up in the BNT-A-treated group while no significant change was found in salivary composition. BNT-A treatment did not change the Streptococcus mutans levels in saliva but there was statistically significant increase in levels of Lactobacilli. BNT-A injections can effectively treat sialorrhea while considering the change of oral microflora, and the patients should be under dentists' care more frequently. EudraCT clinical trial number: 2015-000682-30.
Assuntos
Toxinas Botulínicas Tipo A/uso terapêutico , Fármacos Neuromusculares/uso terapêutico , Doença de Parkinson/tratamento farmacológico , Saliva/efeitos dos fármacos , Sialorreia/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Antiparkinsonianos , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Doença de Parkinson/complicações , Doença de Parkinson/microbiologia , Doença de Parkinson/fisiopatologia , Saliva/microbiologia , Glândulas Salivares/diagnóstico por imagem , Glândulas Salivares/efeitos dos fármacos , Sialorreia/etiologia , Sialorreia/microbiologia , Sialorreia/fisiopatologia , Resultado do Tratamento , UltrassonografiaRESUMO
The medical treatment of Parkinson's disease (PD) is symptomatic both in terms of motor and nonmotor aspects. The nonmotor symptoms therapy should be taken into account as many of them negatively influence the quality of life and are treatable. Botulinum neurotoxin (BoNT) offers effective treatment for drooling and bladder dysfunctions and alternative treatment for constipation and pain related to parkinsonism. BoNT for drooling is probably the best-documented therapy for nonmotor symptoms by clinical trials. Ultrasound-guided injections into parotid and submandibular glands can be recommended as the first line treatment, especially when anticholinergic oral medications are not indicated due to the risk of confusion, cognitive decline, or psychosis. BoNT therapy of constipation and neurogenic bladder is not so well evidenced and the latter indication is based on positive effects in clinical trials in multiple sclerosis and posttraumatic spine injuries. BoNT injections into the salivary glands or bladder are effective and safe with relatively low risk of complications. Authors reviewed the literature on the use of BoNT for all nonmotor aspects of PD, showed their position in guidelines and systematic reviews and gave the practical remarks on injection techniques and dosing.
Assuntos
Inibidores da Liberação da Acetilcolina/administração & dosagem , Toxinas Botulínicas/administração & dosagem , Doença de Parkinson/tratamento farmacológico , Doença de Parkinson/fisiopatologia , Administração Intravesical , Ensaios Clínicos Controlados como Assunto/métodos , Gastroenteropatias/tratamento farmacológico , Gastroenteropatias/epidemiologia , Gastroenteropatias/fisiopatologia , Humanos , Dor/tratamento farmacológico , Dor/epidemiologia , Dor/fisiopatologia , Doença de Parkinson/epidemiologia , Glândula Parótida/efeitos dos fármacos , Glândula Parótida/fisiopatologia , Sialorreia/tratamento farmacológico , Sialorreia/epidemiologia , Sialorreia/fisiopatologia , Glândula Submandibular/efeitos dos fármacos , Glândula Submandibular/fisiopatologia , Resultado do Tratamento , Doenças da Bexiga Urinária/tratamento farmacológico , Doenças da Bexiga Urinária/epidemiologia , Doenças da Bexiga Urinária/fisiopatologiaRESUMO
Abstract The treatment of sialorrhea is necessary for the constant risks posed by hypersalivation. A new therapeutic option comes up with the application of botulinum toxin in salivary glands. However, little is known about its mechanism of action in glandular tissue. Based on the above, this work had the objective to systematically review the literature about the action of botulinum toxin on submandibular and parotid salivary glands tissues. Electronic search was performed in databases of great relevance for this study (PubMed, SciELO, HighWire, Crossref, Scopus, Science Direct, MEDLINE, OLDMEDLINE, Serials Database, NLM Catalog, LILACS and IBECS). Inclusion and exclusion criteria for articles were established, and a total number of 14 articles were selected and used. There are few publications that clarify how the salivary gland acini behave with application of botulinum toxin. Although, the immunohistochemical findings were consistent among authors, showing weak immunoreactivity in glands treated with botulinum toxin. Histometric data are divergent, requiring more detailed studies to answer the questions about the efficacy and safety of botulinum toxin in salivary glands.
Resumo O tratamento da sialorreia se faz necessário pelos constantes riscos trazidos por este estado de hipersalivação. Uma nova opção terapêutica surge com a aplicação da toxina botulínica em glândulas salivares. Entretanto, pouco se sabe sobre o seu mecanismo de ação no tecido glandular. Com base no exposto, este trabalho teve o objetivo de revisar sistematicamente na literatura a ação da toxina botulínica sobre o tecido das glândulas salivares submandibular e parótida. Foi realizada uma busca eletrônica em bases de dados de grande relevância para este estudo (PubMed, SciELO, HighWire, Crossref, Scopus, Science Direct, MEDLINE, OLDMEDLINE, Serials Database, NLM Catalog, LILACS e IBECS). Foram estabelecidos critérios de inclusão e exclusão para os artigos, e um "n" de 14 trabalhos foram selecionados e utilizados. São poucas as publicações que esclarecem como os ácinos das glândulas salivares se comportam mediante aplicação da toxina botulínica. Apesar de os achados imunohistoquímicos entre os autores serem concordantes, com imunorreatividade mais fracas nas glândulas tratadas com a toxina botulínica, os dados histométricos são divergentes e há questionamentos metodológicos, necessitando de mais estudos pormenorizados para responder as questões sobre a eficácia e segurança da toxina botulínica nas glândulas salivares.
Assuntos
Animais , Coelhos , Ratos , Glândulas Salivares/fisiopatologia , Glândulas Salivares/patologia , Sialorreia/fisiopatologia , Sialorreia/patologia , Toxinas Botulínicas Tipo A/toxicidade , Sialorreia/induzido quimicamenteRESUMO
OBJECTIVES: The aim of the present study was to examine the effect of acquired unilateral peripheral facial palsy on speech, communication and oral functions and to study the relationship between the degree of facial palsy and articulation, saliva control, eating ability and lip force. MATERIALS AND METHODS: In this descriptive study, 27 patients (15 men and 12 women, mean age 48years) with unilateral peripheral facial palsy were included if they were graded under 70 on the Sunnybrook Facial Grading System. The assessment was carried out in connection with customary visits to the ENT Clinic and comprised lip force, articulation and intelligibility, together with perceived ability to communicate and ability to eat and control saliva conducted through self-response questionnaires. RESULTS: The patients with unilateral facial palsy had significantly lower lip force, poorer articulation and ability to eat and control saliva compared with reference data in healthy populations. The degree of facial palsy correlated significantly with lip force but not with articulation, intelligibility, perceived communication ability or reported ability to eat and control saliva. CONCLUSION: Acquired peripheral facial palsy may affect communication and the ability to eat and control saliva. Physicians should be aware that there is no direct correlation between the degree of facial palsy and the possible effect on communication, eating ability and saliva control. Physicians are therefore recommended to ask specific questions relating to problems with these functions during customary medical visits and offer possible intervention by a speech-language pathologist or a physiotherapist.
Assuntos
Transtornos da Articulação/fisiopatologia , Paralisia Facial/fisiopatologia , Lábio/fisiopatologia , Inteligibilidade da Fala/fisiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Ingestão de Alimentos/fisiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Sialorreia/fisiopatologia , Inquéritos e Questionários , Adulto JovemAssuntos
Esclerose Lateral Amiotrófica/fisiopatologia , Antagonistas Colinérgicos/uso terapêutico , Transtornos de Deglutição/fisiopatologia , Sialorreia/tratamento farmacológico , Idoso , Amitriptilina/uso terapêutico , Esclerose Lateral Amiotrófica/complicações , Atropina/uso terapêutico , Transtornos de Deglutição/etiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Sialorreia/etiologia , Sialorreia/fisiopatologia , Inquéritos e QuestionáriosRESUMO
The treatment of sialorrhea is necessary for the constant risks posed by hypersalivation. A new therapeutic option comes up with the application of botulinum toxin in salivary glands. However, little is known about its mechanism of action in glandular tissue. Based on the above, this work had the objective to systematically review the literature about the action of botulinum toxin on submandibular and parotid salivary glands tissues. Electronic search was performed in databases of great relevance for this study (PubMed, SciELO, HighWire, Crossref, Scopus, Science Direct, MEDLINE, OLDMEDLINE, Serials Database, NLM Catalog, LILACS and IBECS). Inclusion and exclusion criteria for articles were established, and a total number of 14 articles were selected and used. There are few publications that clarify how the salivary gland acini behave with application of botulinum toxin. Although, the immunohistochemical findings were consistent among authors, showing weak immunoreactivity in glands treated with botulinum toxin. Histometric data are divergent, requiring more detailed studies to answer the questions about the efficacy and safety of botulinum toxin in salivary glands.
Assuntos
Toxinas Botulínicas Tipo A/toxicidade , Glândulas Salivares/patologia , Glândulas Salivares/fisiopatologia , Sialorreia/patologia , Sialorreia/fisiopatologia , Animais , Coelhos , Ratos , Sialorreia/induzido quimicamenteRESUMO
BACKGROUND: Clozapine is the only medication licensed for the treatment of resistant schizophrenia in the UK. Although efficacious, a common and unpopular side effect of clozapine treatment is clozapine-induced hypersalivation (CIH), which can contribute to non-adherence. The standard treatment for CIH in the UK is hyoscine hydrobromide but this may aggravate cognitive deficits in patients with schizophrenia while glycopyrrolate may be an effective alternative with a more tolerable side effect profile. There is currently no convincing evidence for hyoscine, or any other medication, as an effective treatment for CIH. METHODS/DESIGN: This is a multicentre randomised, double-blind, placebo-controlled feasibility study of glycopyrronium bromide (glycopyrrolate) and hyoscine hydrobromide (hyoscine) in patients with clozapine-induced hypersalivation. We aim to recruit 42 patients who have been prescribed clozapine and are experiencing hypersalivation, and randomise them to one of three study arms (either hyoscine, glycopyrrolate or placebo). The primary outcome measures will be the participant recruitment and attrition rates, and the secondary outcome will be the metrics of the daytime hypersalivation measure. After a 1-week washout period (discontinuing CIH medication, if any), there will be a 4-week treatment period where participants will be titrated up to the maximum tolerated dose of hyoscine, glycopyrrolate or placebo. Measurements of daytime salivation, nocturnal salivation, cognition and side effects will be taken during home visits in week 2 and week 5. Information on salivation and side effects will also be taken through telephone calls in week 3 and week 4. To gather information on the experience of study participants, exit interviews will also be requested with all participants who drop out of the study and a sample of participants who complete the study. DISCUSSION: There is currently no convincing evidence for hyoscine, or any other medication, as an effective treatment for CIH. There is promising evidence that glycopyrrolate may be more successful in the treatment of CIH causing fewer cognitive side effects. We propose to conduct a randomised placebo-controlled feasibility study of glycopyrrolate and hyoscine in the treatment of clozapine-induced hypersalivation to inform the design of a future efficacy trial. TRIAL REGISTRATION: Clinicaltrials.gov NCT02613494 , 23 November 2015.
Assuntos
Antipsicóticos/efeitos adversos , Clozapina/efeitos adversos , Glicopirrolato/uso terapêutico , Antagonistas Muscarínicos/uso terapêutico , Salivação/efeitos dos fármacos , Esquizofrenia/tratamento farmacológico , Escopolamina/uso terapêutico , Sialorreia/prevenção & controle , Adolescente , Adulto , Idoso , Protocolos Clínicos , Método Duplo-Cego , Estudos de Viabilidade , Feminino , Glicopirrolato/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Antagonistas Muscarínicos/efeitos adversos , Projetos de Pesquisa , Escopolamina/efeitos adversos , Sialorreia/induzido quimicamente , Sialorreia/diagnóstico , Sialorreia/fisiopatologia , Fatores de Tempo , Resultado do Tratamento , Reino Unido , Adulto JovemRESUMO
OBJECTIVE: Drooling is a common symptom in Parkinson's disease (PD). This study used resting-state functional MRI (fMRI) to evaluate the brain connectivity of cortico-striatal circuits in PD patients with drooling. METHOD: We enrolled 30 early-stage drug-naïve PD patients and 30 matched normal controls. Among the PD patients, 15 patients were classified as "droolers" with the presence of drooling and 15 patients as "non-droolers" with the absence of drooling. All participants underwent resting-state fMRI scans on a 3-T MR system, focusing on the functional connectivity of striatum subregions. RESULTS: Compared with PD patients without drooling, PD patients with drooling showed the significantly reduced functional connectivity of putamen within bilateral sensorimotor cortices, superior and inferior parietal lobules and areas in the right occipital and temporal lobes. No increased functional connectivity was found between the two PD subgroups. In addition, compared with healthy controls, both PD subgroups showed the functional connectivity alterations in cortico-striatal loops. The decreased functional connectivity was prominent in the most affected posterior putamen, and the increased functional connectivity was evident only in the relatively unaffected anterior striatum and caudate. CONCLUSION: By studying a cohort of early-stage drug-naïve PD patients, we eliminated the potential confounding effects of antiparkinson medication on the functional integration of neural networks. We demonstrated decreased connectivity within cortico-striatal networks in PD patients with drooling. These findings might be helpful for promoting the further understanding of neural system effects underlying drooling in PD. Our result is preliminary and further investigation is needed.